Human cytomegalovirus UL84 oligomerization and heterodimerization domains act as transdominant inhibitors of oriLyt-dependent DNA replication: evidence that IE2-UL84 and UL84-UL84 interactions are required for lytic DNA replication.
Human cytomegalovirus (HCMV) UL84 encodes a 75-kDa protein required for oriLyt-dependent DNA replication and interacts with IE2 in infected and transfected cells. UL84 localizes to the nucleus of transfected and infected cells and is found in viral replication compartments. In transient assays it was shown that UL84 can interfere with the IE2-mediated transactivation of the UL112/113 promoter of HCMV. To determine whether UL84 protein-protein interactions are necessary for lytic DNA synthesis, we purified UL84 and used this protein to generate a monoclonal antibody. Using this antibody, we now show that UL84 forms a stable interaction with itself in vivo. The point of self-interaction maps to a region of the protein between amino acids 151 and 200, a domain that contains a series of highly charged amino acid residues. Coimmunoprecipitation assays determined that UL84 interacts with a protein domain present within the first 215 amino acids of IE2. We also show that an intact leucine zipper domain of UL84 is required for a stable interaction with IE2 and UL84 leucine zipper mutants fail to complement oriLyt-dependent DNA replication. UL84 leucine zipper mutants no longer interfere with IE2-mediated transactivation of the UL112/113 promoter, confirming that the leucine zipper is essential for a functional interaction with IE2. In addition, we demonstrate that both the leucine zipper and oligomerization domains of UL84 can act as transdominant-negative inhibitors of lytic replication in the transient assay, strongly suggesting that both an IE2-UL84 and a UL84-UL84 interaction are required for DNA synthesis.
Department of Microbiology and Immunology, University of Nevada-Reno, Reno, Nevada, USA.
Kelly S
KS
Colletti
Yiyang
Y
Xu
Sylvia A
SA
Cei
Margaret
M
Tarrant
Gregory S
GS
Pari
D000911:Antibodies, Monoclonal / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D001665:Binding Sites; D003587:Cytomegalovirus / Q000378:metabolism*; D004261:DNA Replication; D019281:Dimerization; D005347:Fibroblasts; D015967:Gene Expression Regulation, Viral; D019288:Herpesvirus 8, Human; D006801:Humans; D017874:Immediate-Early Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D016350:Leucine Zippers / Q000235:genetics; D009154:Mutation / Q000235:genetics; D011233:Precipitin Tests; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D018741:Replication Origin / Q000235:genetics*; D015534:Trans-Activators / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D015533:Transcriptional Activation; D014764:Viral Proteins / Q000737:chemistry* / Q000276:immunology / Q000302:isolation & purification / Q000378:metabolism*; D014779:Virus Replication
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; C069186:IE2 protein, Cytomegalovirus; D017874:Immediate-Early Proteins; D015534:Trans-Activators; D014764:Viral Proteins; C072218:UL84 protein, Cytomegalovirus